Wedbush Raises Price Target on Pacira Pharma (PCRX) Following 3Q Beat

October 27, 2015 5:20 PM

Wedbush reiterated an Outperform rating on Pacira Pharmaceuticals (NASDAQ: PCRX), and raised the price target to $113.00 (from $106.00), following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found